increased serum interleukin-33 levels in patients with

0 downloads 0 Views 1MB Size Report
57. ENDOCRINE REGULATIONS, Vol. 47, 57–64, 2013 doi:10.4149/endo_2013_02_57 increased serum interleukin-33 levels in patients with Graves' disease.
ENDOCRINE REGULATIONS, Vol. 47, 57–64, 2013

57

doi:10.4149/endo_2013_02_57

Increased serum interleukin-33 levels in patients with Graves’ disease Celik HT, 2Abusoglu S, 3Burnik SF, 4Sezer S, 5Serdar MA, 4Ercan M, 4Uguz N, 6Avcikucuk M, 7Bal Ceylan, 8Yildirimkaya M

1

Biochemistry Department, Turgut Ozal University Faculty of Medicine, Ankara; 2Biochemistry Department, Selcuk University Faculty of Medicine, Konya; 3Endocrinology Clinic, Ankara Numune Training and Education Hospital, Ankara; 4Biochemistry Department, Ankara Numune Training and Education Hospital, Ankara; 5Biochemistry Department, Gulhane Military Medical Academy (GATA), Ankara; 6Biochemistry Department, Kırıkkale Training and Education Hospital, Kirikkale; 7Department of Biochemistry, Occupational Diseases Hospital, Ankara; 8Biochemistry Department, Ankalab Laboratory, Ankara; Turkey E-mail: [email protected] 1

Objective. Interleukin-33 (IL-33), a 30 kDa cytokine, is a member of IL-1 family. It is considered to be an autoimmune biomarker associated with T helper 2 (Th 2) response. γ-interferon is also produced by T helper 1 (Th 1) cells to induce cellular responses. γ-interferon is a 143-amino acid residue glycoprotein with several biological functions including potent anti-viral activity, stimulation of macrophage activity, modulation of Major Histocompatibilty Complex class I/class II expression, and regulation of a diversity of specific immune responses. The aim of this study was to investigate the serum levels of IL-33 and γ-interferon in different thyroid disorders. Methods. Twenty patients with Graves’ disease, 21 patients with Hashimoto hypothyroidism, 21 euthyroid Hashimoto patients, and 27 control subjects were recruited to this study. Blood samples were drawn and IL-33 and γ-interferon tests were analyzed from 89 participants. Serum IL-33 and γ-interferon analyses were performed by enzyme-linked immunosorbent assay. Results. There was no statistically significant difference between groups for serum γ-interferon levels. Serum IL-33 concentrations were significantly higher in Graves’ disease group compared to the other groups (p